Stay updated on Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page
- Check4 days agoChange DetectedAdded a dedicated Locations section with California as a listed study site, clarifying where the trial is conducted. Removed the older California Locations label and the HHS Vulnerability Disclosure link as part of the prior revision.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe terms 'Head and neck squamous cell carcinoma' and the related topic 'MedlinePlus Genetics' have been removed from the page.SummaryDifference0.2%

- Check33 days agoChange DetectedRelated topics were added (Head and neck squamous cell carcinoma; MedlinePlus Genetics) and the page revision label updated from v3.2.0 to v3.3.2. These are metadata updates and do not affect the study details.SummaryDifference0.2%

- Check40 days agoChange DetectedRemoved the government funding lapse notice from the page, which was an operational status message. This change does not affect the study details or eligibility information, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check47 days agoChange DetectedThe related topics list on the page no longer includes 'Head and neck squamous cell carcinoma' and 'MedlinePlus Genetics'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check54 days agoChange DetectedAdded related topics: Head and neck squamous cell carcinoma and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.